Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly

Aart J. van der Lely, Roy Gomez, Andreas Pleil, Xavier Badia, Thierry Brue, Michael Buchfelder, Pia Burman, David Clemmons, Ezio Ghigo, Jens Otto Lunde Jørgensen, Anton Luger, Joli van der Lans-Bussemaker, Susan M. Webb, Christian J. Strasburger

Research output: Contribution to journalArticleResearchpeer-review

21 Citations (Scopus)

Abstract

© 2017, The Author(s). Purpose: Despite availability of multimodal treatment options for acromegaly, achievement of long-term disease control is suboptimal in a significant number of patients. Furthermore, disease control as defined by biochemical normalization may not always show concordance with disease-related symptoms or patient’s perceived quality of life. We developed and validated a tool to measure disease activity in acromegaly to support decision-making in clinical practice. Methods: An international expert panel (n = 10) convened to define the most critical indicators of disease activity. Patient scenarios were constructed based on these chosen parameters. Subsequently, a panel of 21 renowned endocrinologists at pituitary centers (Europe and Canada) categorized each scenario as stable, mild, or significant disease activity in an online validation study. Results: From expert opinion, five parameters emerged as the best overall indicators to evaluate disease activity: insulin-like growth factor I (IGF-I) level, tumor status, presence of comorbidities (cardiovascular disease, diabetes, sleep apnea), symptoms, and health-related quality of life. In the validation study, IGF-I and tumor status became the predominant parameters selected for classification of patients with moderate or severe disease activity. If IGF-I level was ≤1.2x upper limit of normal and tumor size not significantly increased, the remaining three parameters contributed to the decision in a compensatory manner. Conclusion: The validation study underlined IGF-I and tumor status for routine clinical decision-making, whereas patient-oriented outcome measures received less medical attention. An Acromegaly Disease Activity Tool (ACRODAT) is in development that might assist clinicians towards a more holistic approach to patient management in acromegaly.
Original languageEnglish
Pages (from-to)692-701
JournalPituitary
Volume20
Issue number6
DOIs
Publication statusPublished - 1 Dec 2017

Keywords

  • ACRODAT
  • AcroQoL
  • Acromegaly
  • Patient-reported outcomes

Fingerprint Dive into the research topics of 'Development of ACRODAT<sup>®</sup>, a new software medical device to assess disease activity in patients with acromegaly'. Together they form a unique fingerprint.

  • Cite this

    van der Lely, A. J., Gomez, R., Pleil, A., Badia, X., Brue, T., Buchfelder, M., Burman, P., Clemmons, D., Ghigo, E., Jørgensen, J. O. L., Luger, A., van der Lans-Bussemaker, J., Webb, S. M., & Strasburger, C. J. (2017). Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly. Pituitary, 20(6), 692-701. https://doi.org/10.1007/s11102-017-0835-5